Kriya Therapeutics: Gene Therapy. Redefined. Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide Learn more
Pipeline - Kriya Therapeutics Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology
Careers: Future of Gene Therapy - Kriya Therapeutics Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day
Metabolic Disease: Gene Therapy for Diabetes and NASH - Kriya Therapeutics Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin Kriya is initially evaluating its gene therapy in type 1 diabetes
Kriya Provides Update on Pipeline Progress Ahead of Company . . . – Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company enters 2024 with cash balance of $325 million and runway into late 2026 – PALO ALTO, Calif […]
Kriya Announces $320 Million Series D Financing to Advance Pipeline of . . . About Kriya Therapeutics Our mission is to revolutionize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease Kriya is a clinical-stage biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world
Kriya Announces Thirteen Presentations at the American Society of Gene . . . Kriya Announces Thirteen Presentations at the American Society of Gene Cell Therapy (ASGCT) Annual Meeting 2025 – Kriya’s platform includes fully integrated best-in-class manufacturing and research capabilities to support parallel advancement of a broad pipeline of gene therapies –
Kriya Presents Data at the 2025 Association for Research in Vision and . . . KRIYA-825 is designed to be administered through a one-time in-office suprachoroidal injection GA affects approximately two million people in the United States and the European Union Existing treatments require monthly or every-other-month physician-administered intravitreal injections that can be burdensome for patients
Kriya Announces $150 Million Addition to its Series C, Bringing Total . . . Since its founding in October 2019, Kriya has raised over $600 million in committed capital—and with this financing, Kriya’s cash runway is anticipated to run into late 2026 Kriya is developing a portfolio of transformational gene therapies focused on three main therapeutic areas: ophthalmology, neurology and metabolic disease